Mitsu Ikura has been awarded the Robert L. Noble Prize, to
honour his outstanding achievements in cancer research. Dr. Ikura is an
internationally recognized authority in the field of structural biology and has
laid the groundwork for understanding signalling proteins such as cadherins and
catenins and molecular signalling processes involved in human diseases such as
cancer. His studies also provide excellent platforms for developing new drugs
designed to interfere with the functioning of cancer cells.
Dr Ikura is a senior scientist at the Ontario
Cancer Institute/The Campbell Family Cancer Research Institute, and a professor
at the University of Toronto. He received his PhD in macromolecular biophysics
from Hokkaido University, Japan and pursued postdoctoral studies on
multi-dimensional NMR spectroscopy of a calmodulin-kinase peptide complex at
the National Institutes of Health.
Dr Ikura has a Tier-1 Canada Research Chair in
cancer structural biology and has been recognized by many awards and prizes
including the William E. Rawls Prize, the International Research Scholar Award
Howard Hughes Medical Institute, and the Premier’s Research Excellence
He has published over 190 peer-reviewed papers and
has been invited to speak at more than 200 international scientific
Camilla Zimmermann has been awarded The
William E. Rawls Prize, which is given to a young investigator whose work has
led to important advances in cancer control within the past decade.
Dr. Zimmermann is head of palliative services at
University Health Network, palliative care co-lead in the Toronto Central
Regional Cancer Program, Cancer Care Ontario, and associate professor,
department of medicine, University of Toronto. She is also a scientist at the
Ontario Cancer Institute/The Campbell Family Cancer Research Institute and has
her PhD from the University of Toronto.
Dr. Zimmermann has built a remarkable research
program in a short period of time and her progress has been extraordinary. She
has already become an internationally recognized expert in palliative care. She
has published extensively in peer-reviewed journals, including an important
systematic review of the effectiveness of palliative care. In this landmark
paper, she has stimulated critical evaluation of the field and a rethinking of
the methodology of clinical trials in palliative care.
Dr. Zimmermann is interested in determining and
improving the effectiveness of specialized palliative care. Her current
Canadian Cancer Society grant focuses on the effectiveness of early versus
routine specialized palliative team involvement in patients with metastatic
cancer. Outcomes include patient quality of life, satisfaction with care, and